GC-1peptidebenefits The search keyword "gc1 peptide" reveals a common intersection between pharmaceutical research and biochemical entities. While "GC-1" is predominantly identified as Sobetirome, a selective thyromimetic drug that acts as an agonist for thyroid hormone receptors, the inclusion of "peptide" introduces a potential for confusion or a distinct area of inquiry. This article aims to clarify the nature of GC-1, primarily focusing on its role as Sobetirome, and address the less common association with peptides.Sobetirome: the past, present and questions about the future
Sobetirome, also known by its research designation GC-1, is a synthetic compound that mimics the actions of thyroid hormones. Its significance lies in its selective binding and activation of the thyroid hormone receptor beta (TRβ), particularly the TRβ1 subtype, with a much higher affinity than for the TRα receptorInhibitory Peptide of Soluble Guanylyl Cyclase/Trx1 .... This selectivity is crucial because thyroid hormones play a vital role in metabolism, growth, and development, and their receptors are implicated in a range of physiological processes.作者：K Kosar·2020·被引用次数：7—Sobetirome (GC-1) are known to impact lipid and bile acid (BA) metabolism and induce hepatocyte proliferation downstream of Wnt/β-catenin signaling after ...
The therapeutic potential of Sobetirome has been extensively explored, primarily for its effects on metabolic disorders. Research has demonstrated its ability to influence lipid metabolism, reduce cholesterol levels, and promote fat browning—the conversion of white adipose tissue (which stores energy) into brown adipose tissue (which burns energy).Sobetirome These properties make GC-1 a promising candidate for the treatment of conditions like obesity, dyslipidemia, and metabolic syndrome. Studies in animal models have shown that GC-1 can prevent and even reverse fat accumulation without significant adverse effects on heart rate, a common concern with broader thyroid hormone agonists.
The inclusion of "peptide" in the search query "gc1 peptide" can lead to two primary interpretations:
1. Confusion with Biochemical Peptides: In biological contexts, "peptide" refers to short chains of amino acids. While GC-1 (Sobetirome) is a small molecule drug, not a peptide, there are unrelated biological molecules that may share similar nomenclature or be studied in conjunction with thyroid hormone receptorsSobetirome (GC-1) isa thyromimetic drug that binds to the thyroid hormone receptor TRβ1preferentially compared to TRα1.. For instance, some research might involve peptides that interact with or modulate thyroid hormone receptor activity, or peptides used in antibody validation related to specific proteins. The SERP results include mentions of "blocking peptide" for SLC25A22 (GC1) and peptides related to photoreceptor guanylyl cyclase (ROS-GC1), which are distinct from Sobetirome. These are likely to be the source of the "peptide" keyword in some searches, representing a separate area of scientific investigation作者：C Cui·2023·被引用次数：3—Soluble guanylyl cyclase (GC1) and oxido-reductase thioredoxin (Trx1) form a complex that mediates two NO signaling pathways as a function of the redox ....
2. Research or Colloquial Use: In some niche research discussions or informal online forums (like Reddit, as suggested by related searches), researchers or enthusiasts might refer to Sobetirome or related compounds colloquially as "peptides" due to their biological activity or the general category of small molecules used in biological research. However, from a strict chemical and pharmacological standpoint, Sobetirome is not a peptide.
The primary focus of research on GC-1 (Sobetirome) centers on its metabolic effects.GC-1(Sobetirome) is a synthetic thyroid hormone receptor-beta selective agonist extensively studied for its unique biochemical profile, receptor selectivity, ... Its ability to increase metabolic rate and promote the conversion of white fat to brown fat has garnered significant attention as a potential strategy for combating the obesity epidemic. Beyond metabolic disorders, its influence on lipid profiles suggests applications in managing dyslipidemia.Sobetirome
Emerging research also explores GC-1's role in other areas. Its impact on liver cell proliferation and bile acid metabolism has been investigated, hinting at potential applications in liver health and regenerative medicine. The selective activation of TRβ receptors, as opposed to TRα, is critical for minimizing side effects associated with overstimulation of the thyroid system, such as cardiac issues.Gc-1 Sobetirome
It is important to distinguish GC-1 (Sobetirome) from endogenous thyroid hormones (like T3 and T4) and other synthetic thyromimetics. While endogenous hormones have broad physiological roles and can cause significant side effects when administered exogenously, GC-1's design specifically targets the TRβ subtype. This selectivity offers a potential therapeutic advantage by allowing for the modulation of metabolic pathways without the widespread systemic effects, particularly on the cardiovascular system, that might be associated with less selective agents. Other TRβ agonists, such as eprotirome and KB2115, have also been developed, each with its own profile of efficacy and safety.
In summary, "GC-1" overwhelmingly refers to Sobetirome, a selective TRβ agonist with significant therapeutic potential for metabolic disorders like obesity and dyslipidemia. While the term "peptide" may appear in searches related to GC-1, it typically points to distinct biochemical entities or colloquial usage rather than indicating that Sobetirome itself is a peptide. Understanding this distinction is key for anyone researching or engaging with this compound, ensuring clarity in discussions about its chemical nature, biological activity, and potential applications.Sobetirome (GC-1) | TRβ Agonist
Join the newsletter to receive news, updates, new products and freebies in your inbox.